# A Study of CI-1012 in HIV-Infected Patients

> **NCT00002196** · PHASE1 · COMPLETED · sponsor: **Parke-Davis** · enrollment: 32 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** CI-1012

## Key facts

- **NCT ID:** NCT00002196
- **Lead sponsor:** Parke-Davis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 32 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002196, "A Study of CI-1012 in HIV-Infected Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00002196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*